Please login to the form below

Not currently logged in
Email:
Password:

Approvals of generic Eloxatin suspended

A US appeals court has temporarily suspended approvals of generic versions of sanofi-aventis' Eloxatin, delaying competition to its fifth-biggest medicine

A US appeals court has temporarily suspended approvals of generic versions of sanofi-aventis' Eloxatin (oxaliplatin), delaying competition to its fifth-biggest medicine.

France's largest drugmaker has contested the US Food and Drug Administration's (FDA) decision to approve copies of the treatment. The ruling forces rivals, including Hospira and Teva who recently obtained FDA approval, to halt shipments of the drug.

Teva spokesperson Denise Bradley confirmed that the company is "not shipping further product until the legal issue is resolved… We are hopeful to have a decision in the near future."

Hospira stated in a US Securities and Exchange Commission filing that the suspension remains in effect "until such time as the court has an opportunity to consider arguments on this matter."

Eloxatin generated €1.35bn ($1.9bn) in sales for sanofi-aventis last year. The company is under pressure as several of its best-selling drugs, including the blood-thinner Plavix, face generic competition.

18th August 2009

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
bmore group

OUR PROMISE: BETTER HEALTH FROM TRIAL TO TREATMENT.We are a full service, independent network of specialist agencies under one roof....

Latest intelligence

AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...
Combined immunotherapies – potential and pitfalls
‘Combining therapeutic compounds is the first logical step towards better results, namely higher rates of patients responding to treatment, with deeper and more sustained responses’...

Infographics